NCT04072952 - A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer | Biotech Hunter

Enrollment

217

Participants

Timeline

Start Date

August 5, 2019

Primary Completion Date

September 13, 2024

Study Completion Date

November 30, 2025

Conditions

Breast Cancer

Interventions

DRUG

ARV-471

Parts A and B: ARV-471 administered QD or BID for 28 day cycles.

DRUG

ARV-471 in combination with palbociclib (IBRANCE®)

Part C: Daily oral dosages of ARV-471 for 28 days in combination with palbociclib (IBRANCE®) for 21 days

Trial Locations (16)

10461

Clinical Trial Site, The Bronx

28204

Clinical Trial Site, Charlotte

33612

Clinical Trial Site, Tampa

33901

Clinical Trial Site, Fort Myers

37203

Clinical Trial Site, Nashville

48109

Clinical Trial Site, Ann Arbor

60637

Clinical Trial Site, Chicago

63110

Clinical Trial Site, St Louis

90404

Clinical Trial Site, Santa Monica

94158

Clinical Trial Site, San Francisco

94304

Clinical Trial Site, Palo Alto

98109

Clinical Trial Site, Seattle

06856

Clinical Trial Site, Norwalk

02114

Clinical Trial Site, Boston

02215

Clinical Trial Site, Boston

08816

Clinical Trial Site, East Brunswick